- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.08. | Sharp Therapeutics Corp (2): Sharp Therapeutics begins trading on OTCQB | 2 | Stockwatch | ||
| 29.08. | Sharp Therapeutics Corp. Reports Second Quarter 2025 Results and Expands Market Presence with Listing On OTCQB | 370 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its condensed... ► Artikel lesen | |
| 30.07. | Sharp Therapeutics Corp (2): Sharp hires Rho for drug application submission to FDA | 1 | Stockwatch | ||
| 29.07. | Sharp Therapeutics Corp. Engages Rho Inc. to Help Advance Compounds into Clinical Trials for Gaucher Disease | 425 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a preclinical-stage biotechnology company developing... ► Artikel lesen | |
| 22.07. | Sharp Therapeutics Corp (2): Sharp Therapeutics shareholders approve AGM resolutions | 2 | Stockwatch | ||
| 21.07. | Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders | 308 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing small... ► Artikel lesen | |
| 22.05. | Sharp Therapeutics Corp. Reports First Quarter 2025 Results | 357 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 22, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing... ► Artikel lesen | |
| SHARP THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.05. | Sharp Therapeutics Corp (2): Sharp nominates clinical candidate for Gaucher's | 1 | Stockwatch | ||
| 13.05. | Sharp Therapeutics Corp. Nominates Clinical Candidate for Gaucher's Disease | 363 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing... ► Artikel lesen | |
| 21.04. | Sharp Therapeutics Corp (2): Sharp receives $2.5M (U.S.) from warrant exercise | 2 | Stockwatch | ||
| 21.04. | STX PARTNERS LLP and Newlin Investment Co. Exercise Warrants of Sharp Therapeutics Corp. | 346 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing... ► Artikel lesen | |
| 27.01. | Sharp Therapeutics Corp. Completes Share Consolidation | 371 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical stage biotechnology company specializing... ► Artikel lesen | |
| 16.01. | Sharp Therapeutics Corp. Announces Share Consolidation | 283 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 16, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical stage biotechnology company specializing... ► Artikel lesen | |
| 12.12.24 | Sharp Therapeutics Corp. Announces Completion of Qualifying Transaction | 323 | Newsfile | Toronto, Ontario--(Newsfile Corp. - December 12, 2024) - Sharp Therapeutics Corp. (TSXV: EVP.P) ("Sharp Therapeutics"), formerly EVP Capital Inc. ("EVP Capital"), an Ontario corporation is pleased... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 5,520 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,880 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome | Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized... ► Artikel lesen | |
| QIAGEN | 39,470 | +0,71 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 44,180 | +2,74 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| EVOTEC | 6,612 | +4,36 % | Von Abnehmspritzen bis Krebstherapie: Diese Plattform-Technologie greift gleich mehrere Milliardenmärkte an! | Anzeige / WerbungDie moderne Medizin steht vor einer gewaltigen Aufgabe: Immer mehr Menschen leiden an sogenannten Wohlstandserkrankungen wie Adipositas, Diabetes, Multiple Sklerose oder MASH, der gefürchteten... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 7,460 | 0,00 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
| VERA THERAPEUTICS | 29,190 | +1,39 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| BIONTECH | 89,10 | -0,11 % | BioNTech fürchtet neue Zölle, Eli Lilly tritt auf die Bremse, Daimler Truck verliert trotz Rüstungsfantasien und auch Siemens Healthineers zittert | Erst vor wenigen Tagen kam die für viele erleichternde Nachricht, dass eine Zollvereinbarung zwischen den USA und der EU rückwirkend zum 1. August greift, was vor allem Autobauern ein wenig Luft zum... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 26,620 | +2,23 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 37,470 | 0,00 % | What Analysts Are Saying About Kiniksa Pharmaceuticals Stock | ||
| APOGEE THERAPEUTICS | 39,610 | 0,00 % | Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 ... | SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| DISC MEDICINE | 65,86 | -1,86 % | Disc Medicine Inc: Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) | Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30,... ► Artikel lesen | |
| TANGO THERAPEUTICS | 7,690 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,250 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 | ||
| SUMMIT THERAPEUTICS | 20,870 | 0,00 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen |
Das Unternehmen SHARP THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHARP THERAPEUTICS CORP finden Sie auf Wallstreet Online.